ArticleBMC cancer2019
Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Bladder Cancer Incidence Trends in the United States From 2000 to 2020.Cancer reports (Hoboken, N.J.) · 2026Article
- Treating T24 cells with erianin restores gefitinib drug sensitivity by regulating MYLK to inhibit EGFR and EMT processes.American journal of cancer research · 2026Article
- Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Article
- Carcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention.Frontiers in cellular and infection microbiology · 2025Review
- Incidence rates of bladder and kidney cancers among US military servicemen: comparison with the rates in the general US population.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2024Article
- Transitional Cell Carcinoma Arising From the Renal Allograft: A Case Series and Review of the Literature.Cureus · 2024Review
- Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1.NPJ precision oncology · 2024Article
- Trends in genitourinary cancer mortality in the United States: analysis of the CDC-WONDER database 1999-2020.Frontiers in public health · 2024Article
- The trend of schistosomiasis related bladder cancer in the lake zone, Tanzania: a retrospective review over 10 years period.Infectious agents and cancer · 2023Review
- First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure.Contemporary oncology (Poznan, Poland) · 2023Article
- Oncogenic Roles of Polycomb Repressive Complex 2 in Bladder Cancer and Upper Tract Urothelial Carcinoma.Biomedicines · 2022Article
- Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder CarcinomaIranian biomedical journal · 2022Article
- Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma.Current urology · 2022Article
- Trends in the cause of death among patients with bladder cancer in the US SEER population, 1992-2018.World journal of urology · 2022Article
- Incidence trends for twelve cancers in younger adults-a rapid review.British journal of cancer · 2022Review
- Review
- Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer.Journal of the National Cancer Institute · 2022Article
- A rare occurrence of a metastatic urothelial carcinoma to the thoracic vertebra: A case report.Annals of medicine and surgery (2012) · 2022Article
- AhRR methylation contributes to disease progression in urothelial bladder cancer.Cancer biomarkers : section A of Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransitional cell carcinoma (TCC) accounts for around 95% of bladder cancers and is the 4th most common cancer among men and the tenth most common in women, in the US. There is a constant need to clarify current TCC incidence and mortality rates among different population groups for better clinical practice guidelines. We aimed to describe the TCC incidence and incidence-based mortality by demographic and tumor-related characteristics over the last 40 years in the US.
methodsWe obtained data from the SEER 18 registries to study TCC cases that were diagnosed between the years 1973 and 2014. We calculated incidence rates and incidence-based mortality rates in different demographic and tumor-related characteristics and expressed rates by 100,000 person-years. We then calculated the annual changes in incidence and incidence-based mortality rates and displayed them as annual percent changes (APCs).
resultsThere were 182,114 patients with TCC between 1973 and 2014 in the United States. Overall incidence rates of TCC increased 0.16% (95% CI, 0.02-0.30, p = .02) per year over the study period. However, the incidence declined significantly since 2007; (95%CI,-1.89- -0.77, p < .001), except among the elderly and African Americans, which increased significantly over the study period. Overall TCC mortality rates did not change over the study period. However, since 2000 it started to decrease significantly.
conclusionTCC incidence and incidence-based mortality rates had been showing significant increases over the previous decades. However, significant declines in both incidence and incidence-based mortality rates have been observed over the recent years, except in some patients with certain racial groups. Improved understanding of the etiological and ecological factors of TCC could lead to further declines in incidence and incidence-based mortality rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.